183 related articles for article (PubMed ID: 6085395)
1. Behavioral manifestations of movement disorders. Parkinson's and Huntington's disease.
Mayeux R
Neurol Clin; 1984 Aug; 2(3):527-40. PubMed ID: 6085395
[TBL] [Abstract][Full Text] [Related]
2. Monoamine metabolites and neuropeptides in patients with Parkinson's disease, Huntington's chorea, Shy-Drager syndrome, and torsion dystonia.
Lindvall B; Olsson JE
Adv Neurol; 1990; 53():117-22. PubMed ID: 1700581
[No Abstract] [Full Text] [Related]
3. Depression and Parkinson's disease.
Mayeux R; Stern Y; Williams JB; Sano M; Cote L
Adv Neurol; 1987; 45():451-5. PubMed ID: 2435113
[No Abstract] [Full Text] [Related]
4. Clinical and biochemical features of depression in Parkinson's disease.
Mayeux R; Stern Y; Williams JB; Cote L; Frantz A; Dyrenfurth I
Am J Psychiatry; 1986 Jun; 143(6):756-9. PubMed ID: 2424323
[TBL] [Abstract][Full Text] [Related]
5. Dementia in Huntington disease: a cross-sectional analysis of intellectual decline.
Fisher JM; Kennedy JL; Caine ED; Shoulson I
Adv Neurol; 1983; 38():229-38. PubMed ID: 6225315
[No Abstract] [Full Text] [Related]
6. Is "subcortical dementia" a recognizable clinical entity?
Mayeux R; Stern Y; Rosen J; Benson F
Ann Neurol; 1983 Sep; 14(3):278-83. PubMed ID: 6227275
[TBL] [Abstract][Full Text] [Related]
7. Assessment of intellectual function in dementing disorders: validity of WAIS-R short forms for patients with Alzheimer's, Huntington's, and Parkinson's disease.
Randolph C; Mohr E; Chase TN
J Clin Exp Neuropsychol; 1993 Sep; 15(5):743-53. PubMed ID: 8276933
[TBL] [Abstract][Full Text] [Related]
8. Analysis of neurotransmitter metabolites and adenosine 3',5'-monophosphate in the CSF of patients with extrapyramidal motor disorders.
Cramer H; Warter JM; Renaud B
Adv Neurol; 1984; 40():431-5. PubMed ID: 6198888
[No Abstract] [Full Text] [Related]
9. CSF monoamine metabolites, depression, and suicide.
Asberg M; Bertilsson L; Mårtensson B
Adv Biochem Psychopharmacol; 1984; 39():87-97. PubMed ID: 6205566
[No Abstract] [Full Text] [Related]
10. [Effect of fenfluramine in Huntington Chorea].
Roccatagliata G; Pizio N; Farinini D; Firpo MP; Bartolini A; Bacigalupo F; Albano C
Rev Neurol (Paris); 1983; 139(10):589-92. PubMed ID: 6196830
[TBL] [Abstract][Full Text] [Related]
11. The relationship of serotonin to depression in Parkinson's disease.
Mayeux R; Stern Y; Sano M; Williams JB; Cote LJ
Mov Disord; 1988; 3(3):237-44. PubMed ID: 2461509
[TBL] [Abstract][Full Text] [Related]
12. [Evaluation of intellectual functions in patients with Parkinson's disease. Bibliographic review].
Piccirilli M; Piccinin GL; Lamedica A
Riv Patol Nerv Ment; 1981; 101(5):225-46. PubMed ID: 6172833
[TBL] [Abstract][Full Text] [Related]
13. Metabolic studies with bromocriptine in patients with idiopathic parkinsonism and Huntington's chorea.
Kartzinel R; Perlow MD; Carter AC; Chase TN; Calne DB; Shoulson I
Trans Am Neurol Assoc; 1976; 101():53-6. PubMed ID: 141763
[No Abstract] [Full Text] [Related]
14. A double-blind study of zimelidine, a serotonin uptake inhibitor, and desipramine, a norepinephrine uptake inhibitor, in endogenous depression: clinical and biochemical findings.
Aberg-Wistedt A; Ross SB; Jostell KG; Sjöquist B
Adv Biochem Psychopharmacol; 1984; 39():439-47. PubMed ID: 6205564
[No Abstract] [Full Text] [Related]
15. Neurobehavioral aspects of movement disorders.
Glosser G
Neurol Clin; 2001 Aug; 19(3):535-51, v. PubMed ID: 11532642
[TBL] [Abstract][Full Text] [Related]
16. Cerebrospinal fluid homovanillic acid and parkinsonism in Huntington's disease.
Kurlan R; Goldblatt D; Zaczek R; Jeffries K; Irvine C; Coyle J; Shoulson I
Ann Neurol; 1988 Aug; 24(2):282-4. PubMed ID: 2972251
[TBL] [Abstract][Full Text] [Related]
17. Monoamine metabolites in normal human cerebrospinal fluid and in degenerative diseases of the central nervous system.
González-Quevedo A; García JC; Fernández R; Fernández Cartaya L
Bol Estud Med Biol; 1993; 41(1-4):13-9. PubMed ID: 7521168
[TBL] [Abstract][Full Text] [Related]
18. Parkinson's disease, cerebral arteriosclerosis, and senile dementia. Clinical features and response to levodopa.
Parkes JD; Marsden CD; Rees JE; Curzon G; Kantamaneni BD; Knill-Jones R; Akbar A; Das S; Kataria M
Q J Med; 1974 Jan; 43(169):49-61. PubMed ID: 4822972
[No Abstract] [Full Text] [Related]
19. Self-awareness of executive dysfunction in Huntington's disease: comparison with Parkinson's disease and cervical dystonia.
Sitek EJ; Sołtan W; Wieczorek D; Schinwelski M; Robowski P; Harciarek M; Guzińska K; Sławek J
Psychiatry Clin Neurosci; 2013 Jan; 67(1):59-62. PubMed ID: 23331288
[TBL] [Abstract][Full Text] [Related]
20. The basal ganglia and rule-governed language use: evidence from vascular and degenerative conditions.
Longworth CE; Keenan SE; Barker RA; Marslen-Wilson WD; Tyler LK
Brain; 2005 Mar; 128(Pt 3):584-96. PubMed ID: 15659423
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
